Mounjaro can be accompanied by some loss of lean tissue as you lose weight, but current evidence does not show that tirzepatide uniquely or disproportionately wastes muscle. Protein and resistance training are the two practical protections to prioritize.
That answer needs one important qualification: lean mass is not the same thing as muscle. The studies are reassuring in some ways and incomplete in others. This page explains both, without pretending the risk is zero or giving you a reason to panic.
Mounjaro is a UK brand name for tirzepatide, a medicine that acts on GIP and GLP-1 receptors. US readers may know tirzepatide as Mounjaro or Zepbound. This is food and training education, not medication advice; decisions about your treatment belong with your GP, doctor or prescriber.
Does Mounjaro cause muscle loss?
Weight loss from any method usually includes some fat-free tissue as well as fat. Tirzepatide is no exception. The unresolved question is whether it causes more skeletal-muscle loss than expected for the amount of weight lost. The limited evidence so far does not establish that it does.
The language matters:
| Term | What it includes | What it does not prove |
|---|---|---|
| Weight loss | Fat, water and fat-free tissue | That all weight lost was fat |
| Lean mass or fat-free mass | Muscle, organs, bone-associated tissue, body water, glycogen and connective tissue | That every kilogram lost was skeletal muscle |
| Skeletal muscle | The tissue that produces movement and strength | How strong or physically capable someone is |
| Muscle quality | Features such as fat infiltration within muscle | Total muscle amount or function by itself |
Lean mass and fat-free mass are related but not identical measures; studies and devices may define them differently.
This is why a scan showing lower lean mass cannot, on its own, tell us that someone has lost the same amount of working muscle. Changes in water and glycogen can move the number too. Strength and physical function matter alongside body composition.
How much lean mass is lost on tirzepatide?
The most direct Mounjaro evidence comes from two body-composition analyses. A systematic review by Hidalgo Ramos and colleagues in Cureus found only these two eligible clinical studies when it searched the literature through June 2025. That is a small evidence base, and both studies involved Eli Lilly, tirzepatide's manufacturer.
| Study | Who and how it was measured | Main result | What it means |
|---|---|---|---|
| SURMOUNT-1 DXA substudy — Look and colleagues, Diabetes, Obesity and Metabolism | Adults with overweight or obesity; DXA over 72 weeks | Average body weight fell 21.3%; fat mass fell 33.9%; lean mass fell 10.9%. About 75% of weight lost was fat mass and 25% was lean mass. | Absolute lean mass declined, but most weight lost was fat. DXA lean mass is not identical to skeletal muscle. |
| SURPASS-3 MRI post-hoc analysis — Sattar and colleagues, The Lancet Diabetes & Endocrinology | Adults with type 2 diabetes; thigh MRI over 52 weeks | Pooled tirzepatide muscle volume fell 0.64 L, close to the change predicted for the weight lost; muscle fat infiltration fell 0.36 percentage points. | Muscle volume declined, while one marker of muscle composition improved. This was exploratory and did not establish what happened to strength. |
In the SURMOUNT-1 body-composition substudy, the roughly 75% fat / 25% lean split appeared in both the tirzepatide and placebo arms. Estimated treatment differences were −25.7% for fat mass and −8.3% for lean mass. That randomized comparison suggests the medication was not categorically worse for muscle than weight loss in the placebo-plus-lifestyle arm.
SURPASS-3 MRI provides one balancing signal: at the 15 mg dose, the muscle-volume Z-score decline was significantly greater than the population-based estimate (mean difference −0.18, 95% CI −0.29 to −0.07, p=0.0016). This was the one signal suggesting a worse-than-predicted effect at the highest dose.
Here is the honest reading: the SURMOUNT-1 result shows that lean mass formed roughly one-quarter of total loss in that substudy. At pooled doses, SURPASS-3 found less muscle volume close to what its population model predicted for the weight change, alongside reduced fat inside the muscle, but the 15 mg result above limits that reassurance. So the tirzepatide data are mixed, not contradictory: tissue quantity can fall while body composition and muscle quality move in a favorable direction.
Neither study tested a structured resistance-training program. Neither gives a definitive answer about long-term strength, daily function or what happens after many years. Results from a trial average also cannot predict one person's outcome.
For scale, this is an illustration of the SURMOUNT-1 proportion, not a forecast:
| Example total loss | If the study-average split applied | Important limitation |
|---|---|---|
| 20 kg (44 lb / 3 st 2 lb) | About 15 kg (33 lb / 2 st 5 lb) fat mass and 5 kg (11 lb / 0 st 11 lb) lean mass | Your split may be very different, and lean mass is not all muscle |
Why does keeping muscle matter?
Muscle is useful tissue, not merely a cosmetic feature. It helps you stand up, carry groceries, climb stairs, protect your joints and remain independent as you age. It also uses energy at rest and gives your body somewhere to store and use glucose.
Losing muscle may reduce daily energy expenditure somewhat, although becoming a smaller body and moving less also explain much of the usual drop in calorie needs during weight loss. It would be too strong to claim that muscle loss alone “damages” metabolism.
The concern about regain is similarly practical rather than certain: maintaining less muscle and strength may make activity and weight maintenance harder. Current tirzepatide body-composition studies have not proved that a particular amount of lean-mass loss causes regain. The better goal is therefore not “lose no lean mass at any cost.” It is lose mainly fat while protecting strength, function and nutrition.
How much protein should you eat on Mounjaro?
A 2025 joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society proposed higher protein intake during active weight loss, while acknowledging that there is no agreed calculation method for people with obesity.
| Approach | Suggested target | Best use |
|---|---|---|
| Body-weight range proposed during active weight loss | 1.2–1.6 g per kg per day | A starting range to discuss with a dietitian or prescriber |
| Simple absolute target from the joint advisory | 80–120 g per day | Easier when appetite is low or body-weight calculations feel unrealistic |
| General adult reference intake | 0.8 g per kg per day (US RDA; the UK adult RNI is 0.75 g/kg) | A basic population reference, not a muscle-preservation target for active weight loss |
Using actual body weight can overestimate needs for some people with obesity. Kidney disease, older age, diabetes, pregnancy and other medical circumstances can also change what is appropriate. Use our protein calculator to find a starting point, then ask your GP, doctor, prescriber or registered dietitian which weight and target make sense for you.
The body-weight calculation looks like this:
| Example body weight | Proposed daily range at 1.2–1.6 g/kg |
|---|---|
| 70 kg (154 lb / 11 st 0 lb) | 84–112 g |
| 85 kg (187 lb / 13 st 5 lb) | 102–136 g |
| 100 kg (220 lb / 15 st 10 lb) | 120–160 g; actual weight may overestimate need, so personalize this with a professional |
How can you reach protein when your appetite is low?
Do not try to force one enormous evening meal. Spread protein across the meals and snacks you can comfortably manage. Eat the protein part first, before you fill up. Softer options such as Greek yogurt, cottage cheese, eggs, fish, tofu, beans or a milk-based drink may feel easier than a large portion of meat.
Our GLP-1 diet guide shows how to build smaller, nutrient-dense meals around side effects and reduced appetite. Food can do the job; a protein powder is a convenience, not a requirement or a substitute for a varied diet.
If nausea, vomiting, swallowing difficulty or feeling full after a few bites repeatedly stops you eating or drinking enough, contact your prescriber. Persistent weakness, dizziness or dehydration deserves medical attention, not a more complicated meal plan.
Is protein enough to prevent muscle loss?
No. Protein supplies building material; resistance exercise gives your body a reason to keep using it. The joint GLP-1 advisory explicitly warns that more protein alone is unlikely to preserve muscle without structured strength training.
US HHS and CDC physical activity guidelines recommend muscle-strengthening work for all major muscle groups on at least two days a week. The American College of Sports Medicine's 2026 resistance-training position stand supports the simpler message that any resistance training is better than none. Bands, bodyweight, machines and free weights can all work.
| Beginner starting point | Practical target |
|---|---|
| Frequency | 2 whole-body sessions per week on nonconsecutive days |
| Movement pattern | Squat or sit-to-stand; hinge; push; pull; carry or core exercise |
| Starting volume | 1 set per exercise, building gradually to 2–3 sets |
| Repetition range | A controlled set of about 8–12 repetitions, stopping when technique starts to break down |
| Progress | Add a little resistance or an extra repetition when the current work feels comfortably manageable |
You do not need a gym. Start with the beginner home dumbbell workouts and choose loads you can control. If you have pain, balance problems, marked weakness, a heart condition or another reason exercise may not be safe, ask a suitable healthcare professional before starting.
How can you tell whether you are keeping muscle?
A bathroom scale cannot separate fat from muscle. Consumer body-composition scales can be affected by hydration, meals and time of day, so do not let one reading frighten you.
Track a small set of real-world signals instead:
- Are your key exercises holding steady or gradually improving?
- Can you still rise from a chair, climb stairs and carry everyday loads as comfortably?
- Is your waist changing while useful strength remains stable?
- Are you regularly eating enough protein and completing your strength sessions?
Ask your clinician for a more formal assessment if strength is dropping quickly, daily tasks are becoming harder, weight is falling very rapidly, or you are older or already at risk of frailty. They may assess grip strength, walking or chair-rise performance, food intake and—when useful—body composition. Do not change, stop or switch medication based on a smart-scale reading; talk to your prescriber.
What should you do this week?
- Choose a realistic protein target with the caveats above.
- Put a protein food first in each meal you can manage.
- Schedule two short, nonconsecutive whole-body strength sessions.
- Record strength and function as well as scale weight.
- Tell your prescriber early if side effects prevent adequate food or fluid intake.
Want the food and strength plan in one place?
Get The GLP-1 Companion — a $9.99 one-off PDF for building protein-first meals and a muscle-protecting routine around life on a GLP-1. Instant download, no subscription.
FAQ
Does everyone lose muscle on Mounjaro?
No study can say that every person does. Trial averages show some loss of lean mass or muscle volume alongside much larger fat loss, but individual outcomes vary. Protein intake, resistance training, age, starting muscle, rate of loss and health all matter.
Is the lean mass lost on Mounjaro all muscle?
No. Lean mass includes skeletal muscle, but also water, glycogen, organs and connective tissue. DXA cannot treat every change in lean mass as a direct measure of working muscle. MRI can assess muscle volume and fat infiltration more specifically, but strength and function still need separate assessment.
Is Mounjaro worse for muscle than ordinary dieting?
Current evidence has not established that. In SURMOUNT-1, the fat/lean loss split was similar in the tirzepatide and placebo arms. In SURPASS-3 MRI, the pooled reduction in muscle volume was broadly consistent with the amount predicted for the weight lost, although the 15 mg dose showed a significantly greater muscle-volume Z-score decline than predicted. Direct long-term comparisons with well-matched diet-only weight loss are limited, so certainty would be premature.
Can I preserve muscle without going to a gym?
Yes. Progressive bodyweight, resistance-band or dumbbell exercises can train the major muscle groups at home. What matters is repeating the work consistently and making it gradually more challenging. Walking is valuable for health, but it does not replace resistance training for muscle preservation.
Should I drink protein shakes on Mounjaro?
You do not have to. A shake can help when appetite is low, but ordinary foods provide protein plus other nutrients and should usually form the base of your diet. Ask a clinician or dietitian before substantially increasing protein if you have kidney disease or another relevant condition.
Should I stop Mounjaro if I think I am losing muscle?
Do not stop or change prescribed medication based on this article, scale weight or a consumer body-composition reading. Speak to your GP, doctor or prescriber. They can review your rate of loss, symptoms, food intake, strength and treatment in context.
Written by Ricky Valentine · Last updated 31 August 2026
Citations to verify in edit pass: Look M, Dunn JP, Kushner RF, et al., “Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight,” Diabetes, Obesity and Metabolism (2025), doi:10.1111/dom.16275; Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al., “Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial,” The Lancet Diabetes & Endocrinology (2025), doi:10.1016/S2213-8587(25)00027-0; Hidalgo Ramos RA, Hong I, Ortiz M, Secades D, et al., “Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review,” Cureus (2025), PMCID: PMC12394919; Mozaffarian D, Agarwal M, Aggarwal M, et al., “Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society” (2025), doi:10.1177/15598276251344827; US Department of Health and Human Services, Physical Activity Guidelines for Americans, 2nd edition (2018), and CDC muscle-strengthening guidance; American College of Sports Medicine, “Resistance Training Prescription for Muscle Function, Hypertrophy, and Physical Performance in Healthy Adults: An Overview of Reviews,” Medicine & Science in Sports & Exercise (2026); Institute of Medicine, Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (2005), adult protein RDA reference; UK adult Reference Nutrient Intake for protein (0.75 g/kg); NHS, “Tirzepatide: a medicine to manage type 2 diabetes and treat obesity,” reviewed May 2026; Electronic Medicines Compendium, “Mounjaro KwikPen solution for injection in pre-filled pen — Patient Information Leaflet,” updated April 2026.